Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week

Sameer Arora, Kamal Shemisa, Muthiah Vaduganathan, Arman Qamar, Ankur Gupta, Sushil K. Garg, Dharam J. Kumbhani, Helen Mayo, Houman Khalili, Ambarish Pandey, Sandeep R. Das

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor.

Original languageEnglish (US)
Pages (from-to)2454-2464
Number of pages11
JournalJournal of the American College of Cardiology
Volume73
Issue number19
DOIs
StatePublished - May 21 2019

Fingerprint

Secondary Prevention
Dyspnea
clopidogrel
Hemorrhage
Ticagrelor
Incidence
Percutaneous Coronary Intervention
Acute Coronary Syndrome
Aspirin
Meta-Analysis
Decision Making
Randomized Controlled Trials
Physicians

Keywords

  • acute coronary syndrome
  • adherence
  • myocardial infarction
  • secondary prevention
  • ticagrelor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD : JACC Review Topic of the Week. / Arora, Sameer; Shemisa, Kamal; Vaduganathan, Muthiah; Qamar, Arman; Gupta, Ankur; Garg, Sushil K.; Kumbhani, Dharam J.; Mayo, Helen; Khalili, Houman; Pandey, Ambarish; Das, Sandeep R.

In: Journal of the American College of Cardiology, Vol. 73, No. 19, 21.05.2019, p. 2454-2464.

Research output: Contribution to journalReview article

Arora, Sameer ; Shemisa, Kamal ; Vaduganathan, Muthiah ; Qamar, Arman ; Gupta, Ankur ; Garg, Sushil K. ; Kumbhani, Dharam J. ; Mayo, Helen ; Khalili, Houman ; Pandey, Ambarish ; Das, Sandeep R. / Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD : JACC Review Topic of the Week. In: Journal of the American College of Cardiology. 2019 ; Vol. 73, No. 19. pp. 2454-2464.
@article{56e73c99d494411e8ab00bf0bbc8e8f1,
title = "Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week",
abstract = "Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25{\%}; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59{\%} higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor.",
keywords = "acute coronary syndrome, adherence, myocardial infarction, secondary prevention, ticagrelor",
author = "Sameer Arora and Kamal Shemisa and Muthiah Vaduganathan and Arman Qamar and Ankur Gupta and Garg, {Sushil K.} and Kumbhani, {Dharam J.} and Helen Mayo and Houman Khalili and Ambarish Pandey and Das, {Sandeep R.}",
year = "2019",
month = "5",
day = "21",
doi = "10.1016/j.jacc.2019.03.470",
language = "English (US)",
volume = "73",
pages = "2454--2464",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "19",

}

TY - JOUR

T1 - Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD

T2 - JACC Review Topic of the Week

AU - Arora, Sameer

AU - Shemisa, Kamal

AU - Vaduganathan, Muthiah

AU - Qamar, Arman

AU - Gupta, Ankur

AU - Garg, Sushil K.

AU - Kumbhani, Dharam J.

AU - Mayo, Helen

AU - Khalili, Houman

AU - Pandey, Ambarish

AU - Das, Sandeep R.

PY - 2019/5/21

Y1 - 2019/5/21

N2 - Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor.

AB - Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor.

KW - acute coronary syndrome

KW - adherence

KW - myocardial infarction

KW - secondary prevention

KW - ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=85065099146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065099146&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2019.03.470

DO - 10.1016/j.jacc.2019.03.470

M3 - Review article

C2 - 31097167

AN - SCOPUS:85065099146

VL - 73

SP - 2454

EP - 2464

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 19

ER -